In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Praxis Precision Medicines Inc (NASDAQ: PRAX) closed at $294.38 up 0.60% from its previous closing price of $292.63. In other words, the price has increased by $0.60 from its previous closing price. On the day, 0.79 million shares were traded. PRAX stock price reached its highest trading level at $302.34 during the session, while it also had its lowest trading level at $282.185.
Ratios:
For a deeper understanding of Praxis Precision Medicines Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.18 and its Current Ratio is at 5.18. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Oppenheimer on December 15, 2025, Reiterated its Outperform rating but revised its target price to $750 from $250 previously.
On November 19, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $424.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 20 ’25 when Nemiroff Alex sold 25,130 shares for $193.09 per share. The transaction valued at 4,852,256 led to the insider holds 20,832 shares of the business.
Mastrocola Lauren sold 13,600 shares of PRAX for $2,612,244 on Nov 20 ’25. The Principal Accounting Officer now owns 10,442 shares after completing the transaction at $192.08 per share. On Nov 20 ’25, another insider, Nemiroff Alex, who serves as the Officer of the company, bought 25,130 shares for $193.09 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRAX now has a Market Capitalization of 7416931328 and an Enterprise Value of 7094889984. For the stock, the TTM Price-to-Sale (P/S) ratio is 994.23 while its Price-to-Book (P/B) ratio in mrq is 18.14. Its current Enterprise Value per Revenue stands at 950.675 whereas that against EBITDA is -24.219.
Stock Price History:
The Beta on a monthly basis for PRAX is 2.87, which has changed by 3.6338878 over the last 52 weeks, in comparison to a change of 0.1877265 over the same period for the S&P500. Over the past 52 weeks, PRAX has reached a high of $317.72, while it has fallen to a 52-week low of $26.70. The 50-Day Moving Average of the stock is 30.13%, while the 200-Day Moving Average is calculated to be 209.95%.
Shares Statistics:
For the past three months, PRAX has traded an average of 1.08M shares per day and 588150 over the past ten days. A total of 25.01M shares are outstanding, with a floating share count of 23.32M. Insiders hold about 7.44% of the company’s shares, while institutions hold 89.65% stake in the company. Shares short for PRAX as of 1765756800 were 3672170 with a Short Ratio of 3.41, compared to 1763078400 on 3613141. Therefore, it implies a Short% of Shares Outstanding of 3672170 and a Short% of Float of 14.71.
Earnings Estimates
The market rating for Praxis Precision Medicines Inc (PRAX) is a result of the insights provided by 13.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$3.39, with high estimates of -$2.89 and low estimates of -$4.65.
Analysts are recommending an EPS of between -$11.97 and -$14.29 for the fiscal current year, implying an average EPS of -$13.11. EPS for the following year is -$12.67, with 13.0 analysts recommending between -$5.63 and -$20.61.
